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Background: Schizophrenia is among the major causes of disability worldwide and the
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing
concern that this health challenge is not fully understood and efficiently addressed.
Methods: Non-systematic review using searches in PubMed on relevant topics as well as
selection of references based on the authors’ experience from clinical work and research
in the field.
Results: In most countries, the standardized mortality rate in schizophrenia is about 2.5,
leading to a reduction in life expectancy between 15 and 20 years. A major contributor
of the increased mortality is due to CVD, with CVD mortality ranging from 40 to 50% in
most studies. Important causal factors are related to lifestyle, including poor diet, lack of
physical activity, smoking, and substance abuse. Recent findings suggest that there are
overlapping pathophysiology and genetics between schizophrenia and CVD-risk factors,
further increasing the liability to CVD in schizophrenia. Many pharmacological agents used
for treating psychotic disorders have side effects augmenting CVD risk. Although several
CVD-risk factors can be effectively prevented and treated, the provision of somatic health
services to people with schizophrenia seems inadequate. Further, there is a sparseness
of studies investigating the effects of lifestyle interventions in schizophrenia, and there is
little knowledge about effective programs targeting physical health in this population.
Discussion: The risk for CVD and CVD-related deaths in people with schizophrenia is
increased, but the underlying mechanisms are not fully known. Coordinated interventions
in different health care settings could probably reduce the risk. There is an urgent need to
develop and implement effective programs to increase life expectancy in schizophrenia,
and we argue that mental health workers should be more involved in this important task.
Keywords: schizophrenia, mortality, metabolic syndrome X, physical training, lifestyle, cardiovascular diseases
INTRODUCTION
Schizophrenia is a major public health concern, causing extensive
suffering and a large need for costly treatment and care. Schiz-
ophrenia is among the top 10 causes of disability adjusted life
years (DALYs) worldwide (1). The standardized mortality rate
(SMR) calculated by dividing the observed mortality of a cohort
by the expected mortality of an age- and gender-matched cohort
of the general population is considerably elevated in schizophre-
nia. Today, the largest single cause of death in schizophrenia is
cardiovascular disease (CVD) (2, 3), similar to the general pop-
ulation. The aim of this paper is to review clinical and epidemi-
ological evidence for increased CVD mortality in schizophrenia,
possible causes and mechanisms, available treatments and pre-
ventions, and focus the discussion on development and imple-
mentation of effective interventions to increase life expectancy in
schizophrenia.
METHODS
We conducted a non-systematic review. We used PubMed search
terms including “schizophrenia” and “mortality” or “CVD,”
“somatic health,”“screening and interventions,”and included pub-
lications selected based on knowledge generated from our research
in this field as well as clinical experience from working with people
with schizophrenia.
GENERAL MORTALITY IN SCHIZOPHRENIA
Meta-analyses have reported a 2.5- to 3-fold increase in mortal-
ity ratios in schizophrenia (4–8), in both inpatient and outpatient
settings (9). In a recent survey from Australia including 7000 indi-
viduals with psychosis, all deaths in an observation period was
registered and SMR was calculated to be as high as 5.5 (65 deaths),
with even higher rates for young adults (SMR 15; 8–15 deaths)
(10). These mortality ratios are alarming and higher than reported
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in other similar studies. Possibly, this discrepancy may reflect real
variations in SMR in different sub-populations within psychosis
spectrum disorders.
Life expectancy for people with schizophrenia is estimated to be
about 15–20 years shorter than for the general population (2, 11).
A particular cause for concern is that the mortality gap between the
general population and schizophrenia seems to have increased dur-
ing the last decades (8, 12). Death from unnatural causes appears to
be 10–20 times higher in schizophrenia than in the general popu-
lation (2, 4, 13). Suicide and accidents accounted for about 40% of
the extra deaths, while 60% were from natural causes (4, 8, 14, 15).
Increased mortality from natural causes is not a recent phe-
nomenon; two large Scandinavian studies from the first part of
the twentieth century found significantly increased SMRs of 2.1
(16, 17) and 4.0 (16, 17). The main causes of death were tuber-
culosis and pneumonia. The high mortality was ascribed to the
general disease prevalence and lack of antibiotics but also to the
overcrowding, malnutrition, and poor hygiene of large psychiatric
institutions.
CARDIOVASCULAR DISEASE-RELATED DEATHS IN
SCHIZOPHRENIA
Several cohort studies addressing the CVD-related mortality have
been conducted during the last decade. A large retrospective study
from the UK including 46,000 people with a severe mental disor-
der (schizophrenia-spectrum and -bipolar disorder), and 300,000
controls found the hazard ratios for CVD mortality to be three-
fold for the age group 18–49 years and twofold for the age group
50–75 years (18). A retrospective register study from Stockholm
county in Sweden including 7800 persons with schizophrenia
found CVD to be the main cause of death with a SMR of 2.3 and 2.1
for males and females, respectively (13). A more recent prospec-
tive national register study from Sweden involving 8300 persons
with schizophrenia found hazard ratios for CVD mortality to be
3.3 (12 years reduced life expectancy) for women and 2.2 (15 years
reduced life expectancy) for men (19). Another recent prospective
study from Sweden, Finland, and Denmark using registers found
similar SMRs (range 1.6–2.5) for CVD-related deaths in all the
three countries, and life expectancies were 15–20 years shorter than
in the general population (11). The increased rates of CVD-related
deaths have been confirmed also in autopsy studies (20).
POSSIBLE CAUSES OF INCREASED RISK FOR CVD-RELATED
DEATHS IN SCHIZOPHRENIA
METABOLIC SYNDROME AND OBESITY
The metabolic syndrome (MetS) is best seen as a physiological
change with a clustering of interrelated metabolic risk factors
for developing type-2 diabetes and CVD, as well as a variety
of other disorders. The main risk factors are abdominal obe-
sity, elevated blood pressure, dyslipidemia, and insulin resistance,
but lately other mechanisms such as endothelial dysfunction,
inflammatory activity, and stress are also recognized as important
components (21).
Over the last 10 years, schizophrenia has consistently been
shown to be associated with a raised prevalence of the MetS (22–
25). McEvoy and colleagues (24) reported on baseline findings
from 686 persons with chronic schizophrenia in the CATIE Study,
where the prevalence of MetS was over 35% in males and over
50% in females. Saari and colleagues (25) found that people with
schizophrenia from the Northern Finland 1966 Birth Cohort Study
had a fourfold risk of the MetS and that the risk was particularly
increased in young individuals. A recent meta-analysis by Mitchell
and colleagues investigated the prevalence of specific CVD-risk
factors in a schizophrenia population who was either unmedicated
(n= 1325), in first episode (n= 2548), or in the chronic phase
(n= 24892) to a healthy population. They found that about 25% of
the unmedicated and first-episode groups were either overweight,
had elevated blood pressure, or dyslipidemia. This prevalence rate
is lower compared to the chronic group, but higher compared to
an age-matched healthy population (26). However, the same study
reported that the prevalence of type-2 diabetes and hyperglycemia
was the same in young people with schizophrenia and their healthy
peers (26).Taken together, these and other results may suggest that
the increased prevalence of type-2 diabetes in schizophrenia is
related to treatment with second-generation antipsychotics (AP)
(27). However, others have shown that first-episode, drug-naive
patients with schizophrenia have impaired fasting glucose toler-
ance, more insulin resistance, and higher levels of plasma glucose
compared to healthy controls (28).
High CVD morbidity is also found in patients with mental
disorders other than schizophrenia. In a sample of middle-aged
and older patients with psychotic symptoms, the risk for CVD
was increased by 60–70% in patients with mood disorder or
post-traumatic stress disorder (PTSD) relative to the Framing-
ham 10-year risk of CVD (29). In a Finnish study, the prevalence
of MetS in depressed patients was 36% (30). CVD-risk in a sam-
ple of people with major depressive disorder or bipolar disorder
increased with 50% from pre-treatment to 2-year follow-up (31).
Obesity, part of the MetS, is more prevalent among people
with schizophrenia than in the general population (32). Important
causes for obesity include excessive levels of food intake, phys-
ical inactivity, as well as genetic disposition and an imbalanced
interplay between hormones (insulin, leptin, and adiponectin) and
several inflammatory markers (including interleukins, the tumor
necrosis factor family, and C-reactive protein) (21, 33).
In this review, the different components of the MetS and obesity
are further discussed in the specific chapters.
LIFESTYLE
Tobacco smoking and substance use
Smoking has well-known detrimental effects on CVD-risk profile
and mortality (34, 35). Tobacco smoking is about three times more
prevalent in people with schizophrenia than in the general popula-
tion,and the amount of smoking is also higher among smokers (22,
36–38). While tobacco smoking has seen a downturn in the general
population (39), smoking rates do not seem to decline in people
with schizophrenia (40). In a recent Finnish survey of psychotic
disorder, smoking at baseline, along with diabetes, was found to be
the most important predictor of 8-year mortality (41). Tobacco-
related conditions comprised approximately 53% of total deaths
in people with schizophrenia in a recent large cohort study (42).
Prevalence of substance abuse is also high in schizophrenia
(38), and this is problematic as substance use in itself is associ-
ated with lower psychosocial functioning (43, 44), higher risk of
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exacerbations, or relapses and may also have direct adverse somatic
effects (45–48). Recently, mortality from natural causes was found
to be especially high in patients with comorbid substance use dis-
orders (49). However, cannabis use was in one study reported
to be associated with decreased mortality in psychotic disorder,
which was tentatively associated with anti-inflammatory effects
of the endocannabinoid system (50). The most commonly used
illicit substance in schizophrenia is cannabis, followed by amphet-
amines and cocaine (38, 51), although availability and preferences
vary across nations and regions.
The increased substance use and smoking in schizophrenia
may partly be explained by altered reward-seeking behavior and
deficits in the representation of value of stimuli (52, 53). This is
in line with the Reward Deficiency Syndrome model proposed
for substance abuse (54), which seems to be associated with the
pathophysiology of schizophrenia (55) and the biological path-
ways implicated in nicotine dependence and smoking cessation
(56). This model also suggests treatment strategies (54), which may
also have implications for interventions targeting other CVD-risk
factors.
Physical inactivity and poor diet
Schizophrenia is associated with sedentary behavior (57). The
engagement in recommended weekly physical activity was esti-
mated to 26% in people with schizophrenia (58), which was lower
than in the general population (34%) (59). Other studies applying
different assessment tools have also shown that people with schiz-
ophrenia are less active (60, 61) and exercise less (62, 63). Low
levels of physical activity and lack of physical fitness reduce life
expectancy and increase risk for MetS and CVD in the general pop-
ulation (64) as well as in schizophrenia (65). Negative symptoms
typical for schizophrenia include lack of initiative and withdrawal
from activities, often leading to a physically less active life. Passiv-
ity and inadequate motivation might also hinder the pursuit of a
healthy diet. Furthermore, the lack of self-insight in one’s own ill-
ness (66) might complicate the possibilities for health promoting
activities in schizophrenia. During hospital admissions, patients
have more symptoms and lower levels of functioning. Activities
are often restricted and admissions of longer duration may have
considerable impact on activity levels. The nature of an inpatient
psychiatric setting has been considered “obesogenic” (67).
Diets rich in calories, fat, and carbohydrates are an important
cause for MetS and increased CVD-risk (68). A balanced diet may
have potential to reduce the risk for adverse medical conditions
(69–71). Unhealthy diets are prevalent in people with schizo-
phrenia (72). Loss of interest in personal hygiene and physical
maintenance are also possible reasons. Alterations in the reward
system may also contribute to the unhealthy eating patterns (73).
There are indications that dietary habits of the mother may affect
taste preferences in the offspring (74), and this might add to other
factors contributing to unhealthy eating patterns in families.
Poor personal economy is prevalent in schizophrenia (75, 76),
and high levels of unemployment is an important reason (77, 78).
Negative symptoms and cognitive deficits are the main reasons for
work disability (79). Poverty affects the possibilities to engage in a
healthy lifestyle, as access to healthy foods and training facilities is
expensive.
ANTIPSYCHOTIC MEDICATION
With the introduction of chlorpromazine in 1952, the treatment of
schizophrenia was revolutionized, and nowadays medication with
AP drugs is considered a central element in the treatment of psy-
chotic disorders (80). However, until second-generation antipsy-
chotics (SGAs) became available in the 1990s, improvement of
psychosis often came at the cost of extrapyramidal symptoms
and tardive dyskinesia, sometimes causing more subjective suf-
fering to patients than the disorder itself, and making adherence
to treatment a great challenge. At the turn of the last century, meta-
bolic disturbances associated with SGA became a major concern
in the treatment of severe mental disorders. Several meta-analyses
have shown APs to have different liabilities of causing weight gain
and other metabolic side effects. On a group level, clozapine and
olanzapine are considered to be the most obesogenic, closely fol-
lowed by quetiapine, with risperidone, sertindole, and typical APs
in an intermediate position, while aripiprazole, amisulpride, and
ziprasidone seem to carry the lowest risk (81–83).
However, most trials have studied previously treated patients
with prolonged illness, often receiving co-medication with drugs
with their own obesogenic properties. There are few prospective,
long-term studies on the effects of different APs on previously
drug-naïve patients on strict monotherapy. Several treatment
studies have shown results diverging from the apparently clear-
cut panorama of metabolic side effects mentioned above (84, 85).
Interestingly, weight gain on olanzapine appeared more rapidly
while after 12 months it was the same as haloperidol and risperi-
done (86). Furthermore, sensitivity to side effects differs with age,
gender, and ethnicity, as well as individual factors that are not
well understood. In addition, several lines of evidence suggest that
SGAs may have exacerbated existing somatic health issues in schiz-
ophrenia. Metabolic disturbances, such as diabetes and slow blood
sugar uptake, had already been observed and described in the “the
mentally insane” of the pre-AP era (87–89). Likewise, the first
report on AP-induced obesity, shortly after chlorpromazine had
been introduced (90), states that “increase in weight, often consid-
erable,has (previously) been reported with such diverse treatments
as insulin shock, cardiazol, and electric convulsive therapy.”
Antipsychotics constitute a heterogeneous group of drugs that
may influence appetite control, body composition, and meta-
bolic regulation through several pathways, a variety of underlying
mechanisms of action have been proposed. As APs have com-
plex pharmacological actions and interact with most biogenic
amine receptors in the brain, a large number of candidate recep-
tors have been targeted. Kroeze et al. (91) showed that the most
robust predictor of a drug’s propensity to induce weight gain was
its affinity for the H1-histamine receptor (H1R). Through this
mechanism, clozapine and olanzapine have been shown to cause
hyperphagia and weight gain in rats by selective stimulation of
the intra-neuronal enzyme adenosine monophosphate (AMP)-
activated protein kinase (AMPK) in the hypothalamus, thereby
blocking the action of the anorexigenic hormone leptin (92). In
accordance with this, findings from one naturalistic study suggest
that females with inherent high levels of leptin and high insulin
sensitivity might be protected against the obesogenic properties
of olanzapine (93). In addition, weight gain and hyperglycemia
might be related to SGA effects on inflammatory pathways (94).
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On the other hand, dyslipidemia has been shown to be significantly
associated with olanzapine treatment independently of body mass
(95). There are also indications of a direct lipogenic effect of
olanzapine caused by increased expression of lipid biosynthesis
genes (96).
Despite the obvious risks due to metabolic side effects, AP
use has not been consistently shown to increase CVD morbidity
or mortality in schizophrenia. Osborn and colleagues (18) con-
cluded that the excess death rates found among mentally ill people
could not be explained neither by smoking, social deprivation,
nor by the use of AP medication alone, although patients on APs
seemed to be at even greater risk than those without. In a recent
meta-analysis of drug trials with placebo controls, AP use was
not found to be related to increased mortality in schizophrenia,
although the higher general mortality in this patient group was
replicated (97). Furthermore, two large Finnish registry studies
demonstrated reduced mortality from all causes in people with
schizophrenia on long-term treatment with APs (98, 99). Better
somatic care in patients receiving AP medication could be part of
the explanation, however, debate continues on the interpretation
of these findings and the role of APs in the all-over schizophre-
nia mortality (41, 100, 101). In addition, sudden cardiac death in
schizophrenia has in several studies been associated with the use of
APs, most probably related to arrhythmias (102–104). Not every
study confirms this picture; Manu and co-workers (105) found
that unexpected deaths in people with schizophrenia most likely
was due to coronary events and found no hypermortality related
to higher levels of AP-treatment.
SHARED PATHOPHYSIOLOGICAL MECHANISMS IN SCHIZOPHRENIA
AND CVD
Several lines of evidence indicate shared underlying pathobiology
between schizophrenia and CVD, beyond the effects accounted for
by lifestyle and AP medication.
First, this relationship might be due to common genetic fac-
tors that contribute to both comorbid medical conditions and
mortality in schizophrenia (106). In particular, there seems to
be overlapping genes associated with both increased CVD-risk
factors and schizophrenia (107, 108). This might explain recent
findings that first-episode psychosis patients not treated with AP
medication are more likely to have obesity, insulin-resistance, dys-
lipidemia, and hypertension compared with age-matched healthy
controls (26, 109), and the pre-AP era findings mentioned above
(see Antipsychotic Medication). Recent molecular studies have
indicated that there are abnormalities in the glucose metabolism
and insulin signaling pathways in subgroups of unmedicated peo-
ple with schizophrenia indicating a shared genetic vulnerability
between type-2 diabetes and schizophrenia in some cases (110).
Second, many neurotransmitters (dopamine, serotonin, and his-
tamine) implicated in schizophrenia also have peripheral effects
on pancreatic β-cells and adipocytes, which regulates blood glu-
cose levels, obesity, and lipid levels (111–113). Third, pathways
involving the hypothalamic–pituitary–adrenal axis (HPA) might
be involved. First-episode psychosis patients have increased cor-
tisol levels (28) possibly due to environmental stress (114) and
these alterations in the HPA-axis might account for some of
the increased CVD mortality (115). Finally, recent studies have
implicated the immune system in severe mental disorders such as
schizophrenia (116, 117), as well as in CVD (118), and it is possi-
ble that the increased CVD-risk associated with schizophrenia is
related to inflammatory mechanisms (119).
HELP SEEKING AND ACCESS TO SOMATIC HEALTH SERVICES
Patients with severe mental disorders report greater difficulty and
more barriers in accessing primary health care (120). These patient
groups also receive poorer quality of somatic health care services
from hospitals. Thus, there is an increased risk for serious condi-
tions to be undiagnosed or inadequately treated (121, 122). People
with schizophrenia seem to receive less somatic health care also
compared to people with other mental disorders (6, 123–125).
In schizophrenia, it is shown that treatment and prevention for
CVD is suboptimal, and this seems to affect mortality (126, 127).
This is supported by an increased mortality due to other somatic
conditions besides CVD (15).
In the literature, there are a number of reports of people with
schizophrenia who appear to experience little pain despite suf-
fering from painful acute medical conditions, such as myocardial
infarction (128) or perforated bowel (129). A meta-analysis of
12 studies on pain perception in schizophrenia indicated reduced
pain sensitivity (130). The hypoalgesia was also found in drug-free
patients, consistent with clinical observations of reduced sensi-
tivity to pain in schizophrenia reported before the introduction
of APs. Pain insensitivity is also found in the healthy relatives
of patients with schizophrenia, suggesting a genetic component
(131). There is a concern that lack of physical pain sensitivity may
result in potentially serious medical conditions passing undiag-
nosed in schizophrenia (132). There is some evidence that the
insula, a cortical structure with extensive connections to different
parts of the cortex and the limbic system, is affected in schizo-
phrenia. The insula is important in establishing awareness of the
body’s internal state (interoception) and plays a major role in the
processes of pain sensitivity (133). Apart from patient-related bar-
riers, inadequately organized somatic care in the mental health
services and an existing culture with little focus on somatic health
issues in psychiatric or mental health clinics may be an important
part of the explanation (134, 135).
INTERVENTION STUDIES
SMOKING CESSATION
Reducing smoking-related mortality will require the delivery of
effective anti-smoking strategies. Smoking cessation may have
considerable impact on CVD death risk, while just a reduction
in smoking does not seem to have the same effect (136, 137).
Both pharmacological and psychosocial interventions for smok-
ing cessation have been found to be useful in helping people with
schizophrenia quit smoking, but the evidence for a lasting effects
is poor (138). Concerns that individuals with severe mental illness
might suffer negative mental consequences when quitting smoking
seem to have little scientific support (139, 140).
In a Cochrane review of 21 trials (141), pharmacological treat-
ment with bupropion, a dopamine agonist, was found to increase
smoking abstinence rates in smokers with schizophrenia. Another
pharmacological agent, varenicline, a nicotinic receptor partial
agonist, could also facilitate smoking cessation, but with possible
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psychiatric adverse effects. Psychological interventions such as
contingent reinforcement might also help people with schizophre-
nia to quit or reduce smoking in the short-term. At the present
time, there are indications that individuals with schizophrenia can
stop smoking with appropriate help, although, convincing evi-
dence that such interventions have a long-term benefit is lacking.
INCREASED CARDIORESPIRATORY FITNESS
Patients with schizophrenia have low levels of physical activity
(36). Increased physical exercise has beneficial effect on several
CVD-risk factors such as body weight and blood lipid concen-
trations (142) and may reduce mortality (143). Improvement in
physical fitness seems possible in schizophrenia (144, 145) and
improved physical fitness seems likely to reduce the elevated mor-
tality in this patient group (146). A Cochrane database review
concludes that exercise programs are feasible and may improve
mental well-being and overall outcome among patients with schiz-
ophrenia (145), as well as in mental illness in general (147). Positive
results of promoting physical exercise in people with schizophre-
nia in outpatient and day care settings have also been reported
(148–151).
The association between high cardiorespiratory fitness specif-
ically (max oxygen uptake – VO max) and low risk of CVD
(independently of weight reduction) is established in healthy men
and women (152). Studies have shown that people with schiz-
ophrenia have reduced peak oxygen uptake, but are capable of
participating in physical exercise programs, which improve their
peak oxygen uptake (153, 154). The effect of the improvement
seems to be comparable with effects of physical training in healthy
controls and patients with CVD (153).
DIRECT CONTROL OF NUTRIENT UPTAKE AND EXPENDITURE: DIET,
EXERCISE, MEDICATION, AND SURGERY
Obesity is a condition mainly caused by a relative excess intake of
calories versus energy expenditure. A focus on these parameters
(diet and activity) is therefore a natural starting point for pre-
vention and treatment. Effective weight management may best be
reached by the implementation of several measures in an inte-
grated fashion. As there is a complex interplay between the factors
responsible for obesity and the other components of the MetS (e.g.,
hypertension, dyslipidemia, insulin intolerance), effective inter-
ventions will be expected to have effects on several CVD-risk
factors. Diet modifications may hold some of the same bene-
fits as physical activity for reducing CVD-risk (71). Specific diets
(e.g., Mediterranean, nut-enriched) may be favorable in achieving
effects on different aspects of the MetS (155–157).
Studies have shown that weight reduction is possible when
applying specific intervention programs for individuals with psy-
chotic disorders (149, 158). The combined effect of behavioral
intervention, nutritional information, and physical exercise was
investigated in a study of people with schizophrenia and body mass
index (BMI) exceeding 25. The 3-month intervention program
showed significant reduction in weight and BMI, which lasted
12 months (159). Intriguingly, weight reduction was gradual, with
increasing weight loss as the program progressed, in contrast to
weight reductions patterns in diet programs in healthy individuals,
where there is often a larger reduction of weight early on.
People with schizophrenia treated with atypical APs partici-
pated in a 1-year multimodal weight control program, comprising
nutrition, exercise, and behavioral interventions. Clinically signif-
icant reductions in weight and other risk factors for poor somatic
health, including hemoglobin A1c were found in the patients who
participated in the program. In contrast, patients who did not
receive the weight control intervention continued to gain weight
(160). A Cochrane review investigating the effects of 23 random-
ized controlled trials found that modest weight reduction can be
obtained in people with schizophrenia with selective pharmaco-
logical and psychological interventions both on diet and activity
levels (161).
For established obesity or MetS, pharmacological and surgi-
cal treatment may be needed and constitute important adjunctive
measures. Finding safe and effective pharmacological interven-
tions is difficult. Several drugs have been tested for weight reduc-
tion. There is evidence for some efficacy for different classes of
drugs currently on the market such as, e.g., lipase inhibitors (Orli-
stat), antidepressants (Lorcaserin, Bupropion), anticonvulsants
(Topiramat), and also Metformin for the treatment of comorbid
diabetes (162, 163). However, there are problems with the evidence
for sustained effects as most studies have <24 months follow-up.
Amphetamine-like appetite suppressants (e.g., phentermin) are
now mostly banned in western countries because of the potential
for abuse and should probably be avoided in persons vulnerable to
psychosis. Sibutramin was withdrawn from the European markets
in 2010 because of cardiovascular side effects. There is some evi-
dence that medication and low caloric diet interventions are better
than exercise or dietary supplements in maintaining weight loss
(164). Statins may be considered for treatment of dyslipidemia
in schizophrenia. Available evidence suggests similar treatment
response as in the general population (165).
New insights in the metabolism of fats have led to investigation
of the role of the hormone leptin in weight loss; however, any pos-
sible effect seems to be limited only to individuals with a genetic
altered metabolism of leptin (166, 167). Alternative classes of drugs
are under investigation for weight reduction in AP-induced weight
gain in schizophrenia and may hold promise (168, 169). Studies
in schizophrenia are limited and lack data on long-term effects.
However, when other efforts to reduce weight gain have failed, the
use of medication, and perhaps especially Metformin, seems to
have some support in available evidence from systematic reviews
and meta-analyses (170–172). However, no medication for obesity
has been shown to reduce CVD morbidity or mortality (173).
Bariatric surgery, where parts of the digestive system are
removed or bypassed, seems to provide greater weight reduc-
tion and higher rates of remission of type-2 diabetes and MetS
compared to non-surgical interventions according to a recent
meta-analysis limited to 2 years of follow-up (174). There are
preliminary indications that people with schizophrenia receiving
this kind of surgery may have similar outcomes as the general
population (175).
CLINICAL MONITORING
There seems to be a consensus that in patients receiving AP med-
ications, weight, blood glucose, blood pressure, and lipid levels
should be assessed at baseline and monitored regularly. American
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Diabetes Association et al. (176) recommended that weight should
be assessed 4, 8, and 12 weeks after initiating or changing AP med-
ication and quarterly thereafter. Blood pressure, blood glucose,
and lipid levels were to be checked 3 months after initiating AP
therapy. If normal, blood pressure and blood glucose levels should
be assessed every year or more frequently, and lipid levels should be
measured every 5 years or more frequently. Several countries have
implemented national guidelines with similar recommendations,
but the compliance with these guidelines is uncertain (177).
Dealing with the described barriers to adequate somatic health
care for people with schizophrenia could include improving avail-
ability of personnel skilled in detecting signs of CVD as well as
the implementation of routines for checking CVD-risk factors in
the mental health care settings. Current evidence makes it relevant
to consider implementing such assessments also in people with
schizophrenia not receiving AP medication.
If the assessments reveal increased risk factors, several courses
of action are possible and should be planned according to the
needs of the individual patient. However, important measures will
often include change of medication and specific treatment of the
present risk factors according to established guidelines for each
condition.
DISCUSSION
The present evidence provides a clear picture of an increased
mortality rate in schizophrenia, approximately two to three times
higher than in the general population. The majority of the increase
is due to CVD. This is a serious health care issue that has to be
dealt with. The precise origin of the raised vulnerability to CVD
in schizophrenia remains elusive and most likely cannot be attrib-
uted to a single mechanism. In the interpretation of the findings
of increased mortality, there is a problem that very little research is
done on drug-naïve patients, and the full role of AP medications
in these associations is thus problematic to assess. At present, most
authors agree that the causality is multifactorial. Unfortunately, it
is difficult with targeted interventions before the mechanisms are
better known. However, the current review of the causative factors
indicates that there may be several points of action available for
the primary prevention of the increased risk for CVD.
Treatment strategies for reducing the risk-increasing behavior
are easy to implement with few side effects, and, thus, potentially
widely acceptable. However, even though adequate facilities for
physical activities are available, and diet and smoking cessation
programs are conducted, patients do not necessarily take advan-
tage of them. Motivation is needed for a change in behavior.
Many patients are ambivalent or lack motivation to increase their
physical activity. Health care professionals are thus challenged to
assist patients in their motivational process. The cognitive tech-
nique Motivational Interviewing (178) is increasingly being used
in areas of medicine where change in the patients’ behavior is
important (179–181), and the results of pilot studies in cardiol-
ogy are promising (182). The Transtheoretical Model of Change
describes the motivational process and seems applicable in physical
activity programs in severe mental illness populations (183). There
are, however, several other obstacles for lifestyles changes among
patients with severe mental illness than the motivational factors.
Increased symptom load in general, side effects of medication,
socioeconomic problems, staff attitudes, and practical problems
related to provision of services also represent barriers (184). These
should be included in intervention programs.
Secondary prevention of CVD would focus on detection of
the increased somatic risk factors and ease the access to preven-
tion and treatment. Of interest, there is research on possible future
psychiatry-specific forms for biological treatment for the increased
CVD-risk associated with APs (185). The prescription of medica-
tion with potential metabolic side effects should only be done after
a careful cost–benefit analysis for each individual. Special atten-
tion should be paid for drug-naïve patients as well as patients in
older age (80, 186). Psychotropic medication should be followed
by a rigorous monitoring of side effects and changes in CVD-risk
factors, following established guidelines (187, 188). Findings that
the increase in CVD-risk factors occurs early after start of medica-
tion should also guide the monitoring (189). As the use of APs is
not the only risk factor for increased CVD, AP-free patients should
also be monitored for somatic risk factors.
The continuous development and implementation of guide-
lines is important, but the evidence also points to a demand for
somatic proficiency in physicians working in psychiatry and that
other mental health professionals contribute. As a group, people
with schizophrenia do not receive adequate treatment for CVD,
and improving somatic treatment and care in these patients is
the first goal. Access to somatic health care should be improved
by identifying local health care barriers and thereafter reducing
them. Such barriers may exist both in the organization of the
services as well as in the minds of politicians, directors, profession-
als, and patients. The European Psychiatric Association has called
for increased cooperation and shared care between the different
healthcare professionals to screen and treat CVD-risk factors and
diabetes (190). Improved coordination between caretakers and
health care professionals is supported by others (190, 191). To
obtain an integrated system of care based on a holistic biopsy-
chosocial patient perspective perhaps a complete transformation
and reorganization of the current mental health care systems is
needed (192). Increasing the awareness of CVD-risk factors among
psychiatrists and primary care physicians caring for patients with
severe mental illness is also called for (190).
A large fraction of the high mortality in schizophrenia may
represent avoidable deaths (193). To meet this serious chal-
lenge, better understanding of the underlying mechanisms and
improved CVD prevention and treatment are needed. However,
better coordination of the health care system is also needed.
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